AIMS: Nuclear factor-kappaB (NF-kappaB) is a transcription factor induced by a wide range of stimuli, including hyperglycaemia and pro-inflammatory cytokines. It is associated with cardiac hypertrophy and heart failure. It was previously reported that the NF-kappaB-mediated inhibition of proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) might explain the shift in glucose metabolism during cardiac pathological processes induced by pro-inflammatory stimuli, although the specific mechanisms remain to be elucidated. We addressed the specific mechanisms by which exposure to tumour necrosis factor-alpha (TNF-alpha) results in PGC-1alpha down-regulation in cardiac cells and, as a consequence, in the metabolic dysregulation that underlies heart dysfunction and failure. METHODS AND RESULTS: By using coimmunoprecipitation studies, we report for the first time that the p65 subunit of NF-kappaB is constitutively bound to PGC-1alpha in human cardiac cells and also in mouse heart, and that NF-kappaB activation by TNF-alpha exposure increases this binding. Overexpression and gene silencing analyses demonstrated that the main factor limiting the degree of this association is p65, because only the modulation of this protein modified the physical interaction. Our data show that the increased physical interaction between p65 and PGC-1alpha after NF-kappaB activation is responsible for the reduction in PGC-1alpha expression and subsequent dysregulation of glucose oxidation. CONCLUSION: On the basis of these data, we propose that p65 directly represses PGC-1alpha activity in cardiac cells, thereby leading to a reduction in pyruvate dehydrogenase kinase 4 (PDK4) expression and the subsequent increase in glucose oxidation observed during the proinflammatory state.
AIMS: Nuclear factor-kappaB (NF-kappaB) is a transcription factor induced by a wide range of stimuli, including hyperglycaemia and pro-inflammatory cytokines. It is associated with cardiac hypertrophy and heart failure. It was previously reported that the NF-kappaB-mediated inhibition of proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) might explain the shift in glucose metabolism during cardiac pathological processes induced by pro-inflammatory stimuli, although the specific mechanisms remain to be elucidated. We addressed the specific mechanisms by which exposure to tumour necrosis factor-alpha (TNF-alpha) results in PGC-1alpha down-regulation in cardiac cells and, as a consequence, in the metabolic dysregulation that underlies heart dysfunction and failure. METHODS AND RESULTS: By using coimmunoprecipitation studies, we report for the first time that the p65 subunit of NF-kappaB is constitutively bound to PGC-1alpha in human cardiac cells and also in mouse heart, and that NF-kappaB activation by TNF-alpha exposure increases this binding. Overexpression and gene silencing analyses demonstrated that the main factor limiting the degree of this association is p65, because only the modulation of this protein modified the physical interaction. Our data show that the increased physical interaction between p65 and PGC-1alpha after NF-kappaB activation is responsible for the reduction in PGC-1alpha expression and subsequent dysregulation of glucose oxidation. CONCLUSION: On the basis of these data, we propose that p65 directly represses PGC-1alpha activity in cardiac cells, thereby leading to a reduction in pyruvate dehydrogenase kinase 4 (PDK4) expression and the subsequent increase in glucose oxidation observed during the proinflammatory state.
Authors: Nicole E Scharping; Ashley V Menk; Rebecca S Moreci; Ryan D Whetstone; Rebekah E Dadey; Simon C Watkins; Robert L Ferris; Greg M Delgoffe Journal: Immunity Date: 2016-08-02 Impact factor: 31.745
Authors: Xavier Palomer; M Silvia Román-Azcona; Javier Pizarro-Delgado; Ana Planavila; Francesc Villarroya; Brenda Valenzuela-Alcaraz; Fátima Crispi; Álvaro Sepúlveda-Martínez; Irene Miguel-Escalada; Jorge Ferrer; J Francisco Nistal; Raquel García; Mercy M Davidson; Emma Barroso; Manuel Vázquez-Carrera Journal: Signal Transduct Target Ther Date: 2020-02-28
Authors: Sarah Sczelecki; Aurèle Besse-Patin; Alexandra Abboud; Sandra Kleiner; Dina Laznik-Bogoslavski; Christiane D Wrann; Jorge L Ruas; Benjamin Haibe-Kains; Jennifer L Estall Journal: Am J Physiol Endocrinol Metab Date: 2013-11-26 Impact factor: 4.310
Authors: Chunguang Hu; Fengxia Ge; Eiichi Hyodo; Kotaro Arai; Shinichi Iwata; Harrison Lobdell; José L Walewski; Shengli Zhou; Robin D Clugston; Hongfeng Jiang; Cynthia P Zizola; Kalyani G Bharadwaj; William S Blaner; Shunichi Homma; P Christian Schulze; Ira J Goldberg; Paul D Berk Journal: J Mol Cell Cardiol Date: 2013-02-16 Impact factor: 5.000